Pharmacogenomics Services Market Size, Share, Trends and Forecast 2026–2034

The global pharmacogenomics services market is gaining momentum as healthcare providers increasingly use genetic information to guide medication selection and dosage decisions. Pharmacogenomics services help identify how individual genetic variations influence drug response, supporting personalized treatment and reducing the risk of adverse drug reactions. Growing adoption across psychiatry, pain management, oncology, and other therapeutic areas is strengthening demand for genetic testing, data analysis, and clinical interpretation services.

The global pharmacogenomics services market was valued at USD 6.35 billion in 2025 and is projected to grow from USD 6.71 billion in 2026 to USD 10.41 billion by 2034, registering a CAGR of 5.65% during the forecast period. North America held the largest regional share at 42.5% in 2025, while Asia-Pacific is expected to record the fastest growth.

Market Overview

Pharmacogenomics services analyze how genetic differences affect the way individuals respond to medications. These services include genetic testing, drug-response analysis, and clinical interpretation that help healthcare professionals select suitable medicines and determine appropriate dosages. By identifying genetic variations associated with drug metabolism, pharmacogenomic testing can support personalized treatment decisions and help minimize adverse drug reactions.

The market includes products, services, and software used across healthcare and pharmaceutical research. Its applications span cardiovascular disease, infectious diseases, oncology, psychiatry, neurological diseases, and pain management. The growing use of genetic insights in medication planning is encouraging healthcare providers and laboratories to expand pharmacogenomic testing capabilities.

Market Size and Forecast

The pharmacogenomics services market was valued at USD 6.35 billion in 2025. Its value is projected to reach USD 6.71 billion in 2026 and USD 10.41 billion by 2034, registering a CAGR of 5.65% during the 2026–2034 forecast period.

Market expansion is supported by the growing use of personalized medicine and the need to improve medication selection and dosing. Genetic testing can help identify variations that influence the effectiveness and safety of certain drugs, making pharmacogenomic analysis relevant across multiple clinical specialties. North America held a 42.5% market share in 2025, while Asia-Pacific is projected to grow at the fastest CAGR of 12.36% through 2034.

Market Drivers

Growing Adoption in Psychiatric Care

The use of pharmacogenomic testing in psychiatric care is supporting demand for services that help clinicians select medications based on individual genetic profiles. Variations in genes such as CYP2D6 and CYP2C19 can influence how patients metabolize antidepressants and other psychiatric medicines, affecting treatment response and the likelihood of side effects. Genetic testing can provide additional information for medication selection and dosage decisions in patients with depression and other mental health conditions. Greater adoption of these tests across hospitals and specialized clinics is supporting market demand.

Demand for Precision Dosing in Pain Management

The need for safer and more effective pain treatment is encouraging the use of pharmacogenomic services. Genetic variations, particularly those involving CYP2D6, can affect how individuals respond to certain opioid medications. Testing can help clinicians assess a patient's likely response to medicines such as codeine and consider alternative treatments when appropriate. This focus on personalized pain management is expanding the role of genetic testing and clinical interpretation services.

Market Challenges

Clinical Integration and Data Accessibility

The integration of pharmacogenomic information into routine prescribing workflows remains an important consideration for market adoption. Genetic results need to be accessible when healthcare professionals make medication decisions, making electronic health record integration and clinical decision-support tools important to service delivery. The growing focus on integrating pharmacogenomic results into electronic health records reflects the need to make genetic insights more accessible during clinical decision-making.

The supplied report data does not identify a separate quantified market restraint. Therefore, this challenge is limited to the clinical integration considerations reflected in the reported market trends.

Market Opportunities

Expansion of Preemptive Pharmacogenomic Screening

Preemptive screening creates opportunities for pharmacogenomic service providers by allowing genetic variations to be assessed before medications are prescribed. Testing inherited variations in drug-metabolizing enzymes and transporters can help clinicians anticipate differences in drug response across multiple therapeutic areas. Wider use of screening panels across healthcare settings can support demand for genetic testing, laboratory analysis, and clinical interpretation services.

Integration with Electronic Health Records

The integration of pharmacogenomic results into electronic health records creates opportunities for software providers and healthcare technology companies. Clinical decision-support tools can interpret gene-drug interactions and provide prescribing alerts when a medication may require an alternative or dosage adjustment. Wider integration can make genetic information available during routine clinical workflows and support the adoption of digital pharmacogenomics services.

Market Segmentation

By Type

Products held the largest share of the pharmacogenomics services market at 46.8% in 2025, supported by demand for genotyping kits, sequencing instruments, and other tools used in genetic analysis. Their role in identifying genetic variations and supporting personalized treatment selection reinforces the segment's leading position.

Software is projected to record the fastest growth, with a CAGR of 11.48%. Demand for genomic data analysis, clinical interpretation, and integration of genetic insights into treatment decisions is supporting adoption of bioinformatics and clinical decision-support solutions.

By Products

Genotyping kits accounted for the largest share of the products segment at 31.6% in 2025. Their role in identifying genetic variations associated with drug response supports their use in pharmacogenomic testing and personalized medication selection.

Sequencing instruments are projected to register the fastest growth, with a CAGR of 10.41%. Improvements in sequencing technologies and the ability to generate detailed genetic information are supporting their adoption in comprehensive genomic analysis and precision medicine.

By Services

Genetic testing services are projected to grow at a CAGR of 10.64%, supported by demand for assessments that identify genetic variations affecting drug efficacy and safety. Their contribution to personalized treatment decisions supports adoption across healthcare settings.

Pharmacogenomic consulting is expected to register a CAGR of 9.91%. The need for expert interpretation of genetic test results and guidance on medication selection and dosage optimization is supporting demand for consulting services.

By Software

Bioinformatics software held the largest share of the software segment at 32.2% in 2025. Its role in processing, analyzing, and interpreting complex genomic data supports its use across pharmacogenomic testing and research workflows.

Clinical decision support systems are projected to record the fastest growth, with a CAGR of 12.46%. Their ability to incorporate genetic information into prescribing decisions and help healthcare professionals identify suitable medications and dosages is supporting segment expansion.

By Technology

Next-generation sequencing held the largest share of the technology segment at 34.7% in 2025. Its ability to analyze multiple genetic variations and generate comprehensive genomic information supports its use in pharmacogenomic testing and precision medicine.

Next-generation sequencing is also projected to register the fastest growth, with a CAGR of 11.36%. Improvements in sequencing accuracy, throughput, and cost efficiency are supporting wider adoption of comprehensive genetic profiling for personalized drug selection.

By Application

Oncology accounted for the largest share of the application segment at 28.6% in 2025. Genetic profiling helps identify variations that influence responses to cancer medicines, supporting treatment selection and the use of targeted therapies.

Oncology is also projected to record the fastest growth, with a CAGR of 11.42%. The expanding use of precision oncology and genetic testing to guide treatment decisions is expected to support demand for pharmacogenomic applications in cancer care.

By End User

Clinical laboratories held the largest share of the end-user segment at 35.4% in 2025. Their role in conducting genetic tests, analyzing patient samples, and providing results to healthcare professionals supports their leading position in the market.

Pharmaceutical companies are projected to register the fastest growth, with a CAGR of 10.91%. The use of pharmacogenomic data in drug development, clinical trials, and personalized medicine research is strengthening demand from this segment.

Regional Analysis

North America

North America dominated the pharmacogenomics services market with a 42.5% share in 2025. The region benefits from established healthcare and research infrastructure, along with initiatives supporting the integration of genetic information into clinical practice.

In the U.S., National Institutes of Health research initiatives extending to 2030 are supporting pharmacogenomics implementation. The NIH RePORTER programme highlights that approximately 15–20% of FDA-approved medications are affected by common genetic variations, creating scope for broader genetic testing and personalized prescribing. In Canada, the Canadian Genomics Strategy is backed by CAD 175.1 million in federal funding over seven years from 2024–25 to advance personalized medicine and genomic applications.

Asia-Pacific

Asia-Pacific is projected to be the fastest-growing regional market, registering a CAGR of 12.36% during 2026–2034. Expanding genomic research, government initiatives, and growing interest in personalized medicine are supporting the region's growth prospects.

Japan is supporting genomic drug-discovery and personalized-medicine research through AMED funding in FY2026. In China, the 2026–2030 pharmaceutical industry plan targets annual growth of at least 20% in the innovative-drug sector, while the Healthy China 2030 strategy supports precision medicine and health-data sharing. India's GenomeIndia initiative has completed whole-genome sequencing of more than 10,000 individuals from 99 population groups and is building a biobank of 20,000 samples, creating a foundation for population-specific pharmacogenomic testing.

Europe

Europe accounted for 27.4% of the pharmacogenomics services market in 2025. Regional development is supported by initiatives to expand genomic research, integrate genetic information into healthcare, and advance personalized treatment.

In the U.K., the Government's Life Sciences Sector Plan targets more than 500,000 genomes in the Genomics England research database by 2030 and up to 5 million participants in the Our Future Health programme. Germany's genome-sequencing pilot, launched in July 2024 with a minimum five-year implementation period, aims to integrate genomic medicine into healthcare and support individualized treatment.

Key Players

The pharmacogenomics services market is moderately fragmented, with competition among diagnostic laboratories, genomic testing companies, pharmaceutical service providers, biotechnology firms, and precision medicine companies. The leading participants identified in the report include:

1. Thermo Fisher Scientific Inc.

2. Admera Health, LLC

3. Agena Bioscience, Inc.

4. Illumina, Inc.

5. OneOme, LLC

6. Myriad Genetics, Inc.

7. Quest Diagnostics Incorporated

8. Dynamic DNA Laboratories

Companies compete through testing accuracy, genetic data interpretation, laboratory infrastructure, clinical validation, test coverage, turnaround time, and partnerships with healthcare providers and pharmaceutical companies. Emerging providers also focus on sequencing technologies, AI-driven genetic analysis, personalized reporting platforms, and specialized gene panels.

Key Industry Developments

• January 2026: Genomind received a U.S. Department of Defense contract to support the Defense Health Agency's pharmacogenomics implementation project for active-duty service members, including the integration of genetic insights into military health records.

• September 2025: Quest Diagnostics launched an advanced pharmacogenomics service using personalized insights from Coriell Life Sciences to support medication selection and prescribing decisions across multiple clinical specialties.

Conclusion

The pharmacogenomics services market is projected to expand from USD 6.71 billion in 2026 to USD 10.41 billion by 2034, supported by growing adoption of personalized medicine, genetic testing, and precision dosing. Products currently represent the largest type segment, while software is expected to record the fastest growth. Oncology remains the leading and fastest-growing application, reflecting the importance of genetic insights in personalized cancer treatment.

North America leads the market, while Asia-Pacific offers strong growth potential through expanding genomic research and precision medicine initiatives. Advances in preemptive screening and electronic health record integration are also creating opportunities for testing providers, software developers, and clinical laboratories.

 Report: http://straitsresearch.com/report/pharmacogenomics-services-market